Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis

被引：8

作者：

Zhang, Liulu ^{[1
]}

Chen, Yuanqi ^{[1
,2
]}

Cheng, Min-Yi ^{[1
]}

Zhuang, Xiaosheng ^{[3
]}

Zou, Jiachen ^{[1
]}

Wei, Dannuo ^{[4
]}

Lin, Ying-Yi ^{[1
]}

Zhang, Yi ^{[1
]}

Wang, Kun ^{[1
]}

机构：

[1] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Breast Canc, Ctr Canc, 106 Zhongshan Er Rd, Guangzhou 510080, Peoples R China

[2] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China

[3] Chinese Univ Hong Kong, Sch Life Sci, Dept Cell & Mol Biol, Shatin, Hong Kong, Peoples R China

[4] Univ Hong Kong, Dept Social Work & Social Adm, Pokfulam, Hong Kong, Peoples R China

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2022年 / 14卷

基金：

中国国家自然科学基金;

关键词：

homologous recombination deficiency; platinum-based chemotherapy; triple-negative breast cancer; PATHOLOGICAL COMPLETE RESPONSE; PHASE-II; CARBOPLATIN; DOXORUBICIN; CYCLOPHOSPHAMIDE; GEMCITABINE; SENSITIVITY; GEPARSIXTO; CISPLATIN; REPAIR;

D O I：

10.1177/17588359221096253

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Recent studies have shown that homologous recombination deficiency (HRD) may be correlated with the pathological complete response (pCR) rate. This meta-analysis aimed to determine the predictive value of HRD for the pCR rate in patients with triple-negative breast cancer (TNBC) receiving platinum-based neoadjuvant chemotherapy (NCT). Methods: Published articles were searched in the PubMed, Embase, Medline, Web of Science, and Cochrane databases up to 1 June 2021, and studies reporting the pCR rate for HRD carriers on platinum-based NCT were selected. Odds ratios (ORs) with 95% confidence intervals (CIs) were determined for the pCR rate, clinical response rate, and Grade 3 or higher adverse events (AEs) using the random-effects model. Bias risk was evaluated using the Cochrane Collaboration tool (PROSPERO, registration number CRD42021249874). Results: Seven studies were eligible. The results showed that HRD carriers had higher pCR rates than non-HRD carriers across all treatment arms (OR = 3.84, 95% CI = [1.93, 7.64], p = 0.0001). Among HRD carriers, the pCR rate was higher in patients on platinum-based NCT than in those without platinum exposure (OR = 1.95, 95% CI = [1.17, 3.23], p = 0.01). We did not observe marked pCR improvements in non-HRD carriers. Among HRD carriers, the pCR rates in the mutant and wild-type breast cancer susceptibility gene (BRCA) groups did not differ significantly (OR = 2.00, 95% CI = [0.77, 5.23], p = 0.16), but HRD carriers with wild-type BRCA had a significant advantage over non-HRD carriers on platinum-based NCT (OR = 3.64, 95% CI = [1.83, 7.21], p = 0.0002). Conclusion: HRD is an effective predictor of increased pCR rates in platinum-based NCT, especially in wild-type BRCA patients. Adding platinum to NCT for non-HRD carriers can increase the incidence of AEs but may not improve the therapeutic effect.

引用

页数：14

共 42 条

[21] Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto [J].

Loibl, S. ;

Weber, K. E. ;

Timms, K. M. ;

Elkin, E. P. ;

Hahnen, E. ;

Fasching, P. A. ;

Lederer, B. ;

Denkert, C. ;

Schneeweiss, A. ;

Braun, S. ;

Salat, C. T. ;

Rezai, M. ;

Blohmer, J. U. ;

Zahm, D. M. ;

Jackisch, C. ;

Gerber, B. ;

Klare, P. ;

Kuemmel, S. ;

Schem, C. ;

Paepke, S. ;

Schmutzler, R. ;

Rhiem, K. ;

Penn, S. ;

Reid, J. ;

Nekljudova, V. ;

Hartman, A-R ;

von Minckwitz, G. ;

Untch, M. .

ANNALS OF ONCOLOGY, 2018, 29 (12) :2341-2347

[22] Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial [J].

Loibl, Sibylle ;

O'Shaughnessy, Joyce ;

Untch, Michael ;

Sikov, William M. ;

Rugo, Hope S. ;

McKee, Mark D. ;

Huober, Jens ;

Golshan, Mehra ;

von Minckwitz, Gunter ;

Maag, David ;

Sullivan, Danielle ;

Wolmark, Norman ;

McIntyre, Kristi ;

Lorenzo, Jose J. Ponce ;

Metzger Filho, Otto ;

Rastogi, Priya ;

Symmans, W. Fraser ;

Liu, Xuan ;

Geyer, Charles E., Jr. .

LANCET ONCOLOGY, 2018, 19 (04) :497-509

[23] Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial [J].

Masuda, Norikazu ;

Bando, Hiroko ;

Yamanaka, Takashi ;

Kadoya, Takayuki ;

Takahashi, Masato ;

Nagai, Shigenori E. ;

Ohtani, Shoichiro ;

Aruga, Tomoyuki ;

Suzuki, Eiji ;

Kikawa, Yuichiro ;

Yasojima, Hiroyuki ;

Kasai, Hiroi ;

Ishiguro, Hiroshi ;

Kawabata, Hidetaka ;

Morita, Satoshi ;

Haga, Hironori ;

Kataoka, Tatsuki R. ;

Uozumi, Ryuji ;

Ohno, Shinji ;

Toi, Masakazu .

BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (01) :117-131

[24] TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker [J].

Mayer, E. L. ;

Abramson, V ;

Jankowitz, R. ;

Falkson, C. ;

Marcom, P. K. ;

Traina, T. ;

Carey, L. ;

Rimawi, M. ;

Specht, J. ;

Miller, K. ;

Stearns, V ;

Tung, N. ;

Perou, C. ;

Richardson, A. L. ;

Componeschi, K. ;

Trippa, L. ;

Tan-Wasielewski, Z. ;

Timms, K. ;

Krop, I ;

Wolff, A. C. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2020, 31 (11) :1518-1525

[25]

Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n160, 10.1136/bmj.n71]

[26] Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis [J].

Poggio, F. ;

Bruzzone, M. ;

Ceppi, M. ;

Ponde, N. F. ;

La Valle, G. ;

Del Mastro, L. ;

de Azambuja, E. ;

Lambertini, M. .

ANNALS OF ONCOLOGY, 2018, 29 (07) :1497-1508

[27] Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation [J].

Popova, Tatiana ;

Manie, Elodie ;

Rieunier, Guillaume ;

Caux-Moncoutier, Virginie ;

Tirapo, Carole ;

Dubois, Thierry ;

Delattre, Olivier ;

Sigal-Zafrani, Brigitte ;

Bollet, Marc ;

Longy, Michel ;

Houdayer, Claude ;

Sastre-Garau, Xavier ;

Vincent-Salomon, Anne ;

Stoppa-Lyonnet, Dominique ;

Stern, Marc-Henri .

CANCER RESEARCH, 2012, 72 (21) :5454-5462

[28] Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer [J].

Rugo, H. S. ;

Olopade, O. I. ;

DeMichele, A. ;

Yau, C. ;

van 't Veer, L. J. ;

Buxton, M. B. ;

Hogarth, M. ;

Hylton, N. M. ;

Paoloni, M. ;

Perlmutter, J. ;

Symmans, W. F. ;

Yee, D. ;

Chien, A. J. ;

Wallace, A. M. ;

Kaplan, H. G. ;

Boughey, J. C. ;

Haddad, T. C. ;

Albain, K. S. ;

Liu, M. C. ;

Isaacs, C. ;

Khan, Q. J. ;

Lang, J. E. ;

Viscusi, R. K. ;

Pusztai, L. ;

Moulder, S. L. ;

Chui, S. Y. ;

Kemmer, K. A. ;

Elias, A. D. ;

Edmiston, K. K. ;

Euhus, D. M. ;

Haley, B. B. ;

Nanda, R. ;

Northfelt, D. W. ;

Tripathy, D. ;

Wood, W. C. ;

Ewing, C. ;

Schwab, R. ;

Lyandres, J. ;

Davis, S. E. ;

Hirst, G. L. ;

Sanil, A. ;

Berry, D. A. ;

Esserman, L. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (01) :23-34

[29]

Schwarzer G., 2007, R News, V7, P40

[30] Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing [J].

Sharma, Priyanka ;

Klemp, Jennifer R. ;

Kimler, Bruce F. ;

Mahnken, Jonathan D. ;

Geier, Larry J. ;

Khan, Qamar J. ;

Elia, Manana ;

Connor, Carol S. ;

McGinness, Marilee K. ;

Mammen, Joshua M. W. ;

Wagner, Jamie L. ;

Ward, Claire ;

Ranallo, Lori ;

Knight, Catherine J. ;

Stecklein, Shane R. ;

Jensen, Roy A. ;

Fabian, Carol J. ;

Godwin, Andrew K. .

BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (03) :707-714

← 1 2 3 4 5 →